<DOC>
	<DOC>NCT01086410</DOC>
	<brief_summary>The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system</brief_summary>
	<brief_title>Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Outpatient with ability to comply with study requirements and complete two 24hour clinic visits Clinical diagnosis of asthma for greater than/equal to 12 weeks Reversibility FEV1 of at least twelve percent and two hundred milliliters FEV1 greater than or equal to fifty percent of predicted History of life threatening asthma Respiratory infection or oral candidiasis Asthma exacerbation Uncontrolled disease or clinical abnormality Allergies to study drugs, study drugs' excipients, medications related to study drugs Taking another investigational medication or prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HPA axis</keyword>
</DOC>